Sinopharm Group Co., Ltd. Class H

As of December 31, 2025, Sinopharm Group Co., Ltd. Class H carries a market capitalization of 60.67B, placing it among publicly traded companies globally. Its enterprise value stands at 141.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sinopharm Group Co., Ltd. Class H's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Sinopharm Group Co., Ltd. Class H has 3.12B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Sinopharm Group Co., Ltd. Class H maintains a current ratio of 1.41, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Sinopharm Group Co., Ltd. Class H's stock has declined approximately 21.65% over the past 52 weeks. The 50-day moving average sits at 15.51, while the 200-day moving average is 18.15.

As of December 31, 2025, Sinopharm Group Co., Ltd. Class H holds 54.30B in cash and equivalents against 78.97B in total debt, resulting in a net debt position of 20.22B. Total book value stands at 93.43B, with working capital of 111.37B providing operational flexibility.